Lyssikatos Joseph P 4
4 · Enliven Therapeutics, Inc. · Filed Sep 23, 2025
Insider Transaction Report
Form 4
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
Transactions
- Sale
Common Stock
2025-09-19$20.02/sh−2,130$42,634→ 933,188 total(indirect: See footnote) - Sale
Common Stock
2025-09-19$19.11/sh−4,870$93,063→ 935,318 total(indirect: See footnote)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $18.94 to $19.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
- [F4]This transaction was executed in multiple trades at prices ranging from $19.95 to $20.0469. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.